title: Treatment of passive experimental autoimmune encephalomyelitis in SJL mice with a recombinant TCR ligand induces IL-13 and prevents axonal injury.
abstract: The major goal of this study was to evaluate the efficacy and mechanism of a rTCR ligand (RTL) construct (I-A(s)/proteolipid protein (PLP)-139-151 peptide = RTL401) for treatment of SJL/J mice developing passive experimental autoimmune encephalomyelitis (EAE) that did not involve coimmunization with the highly inflammatory CFA. Our results demonstrated clearly that RTL401 was highly effective in treating passive EAE, with kinetics of recovery from disease very similar to treatment of actively induced EAE. The potent RTL401 treatment effect was reflected by a partial reduction of infiltrating mononuclear cells into CNS, minimal inflammatory lesions in spinal cord, and preservation of axons injured in vehicle-treated mice during the progression of EAE. Interestingly, in the absence of CFA, RTL401 treatment strongly enhanced production of the Th2 cytokine, IL-13, in spleen, blood, and spinal cord tissue, with variable effects on other Th1 and Th2 cytokines, and no significant effect on the Th3 cytokine, TGF-beta1, or on FoxP3 that is expressed by regulatory T cells. Moreover, pretreatment of PLP-139-151-specific T cells with RTL401 in vitro induced high levels of secreted IL-13, with lesser induction of other pro- and anti-inflammatory cytokines. Given the importance of IL-13 for protection against EAE, these data strongly implicate IL-13 as a dominant regulatory cytokine induced by RTL therapy. Pronounced IL-13 levels coupled with marked reduction in IL-6 levels secreted by PLP-specific T cells from blood after treatment of mice with RTL401 indicate that IL-13 and IL-6 may be useful markers for following effects of RTL therapy in future clinical trials in multiple sclerosis.
authors.affiliation: Neuroimmunology Research, Veterans Affairs Medical Center, Portland, OR 97239, USA. offnerva@ohsu.edu
authors.forename: Halina
authors.initials: H
authors.lastname: Offner
authors.forename: Sandhya
authors.initials: S
authors.lastname: Subramanian
authors.forename: Chunhe
authors.initials: C
authors.lastname: Wang
authors.forename: Michael
authors.initials: M
authors.lastname: Afentoulis
authors.forename: Arthur A
authors.initials: AA
authors.lastname: Vandenbark
authors.forename: Jianya
authors.initials: J
authors.lastname: Huan
authors.forename: Gregory G
authors.initials: GG
authors.lastname: Burrows
mesh_terms: D000818:Animals; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy*; D018984:Epitopes, T-Lymphocyte / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D007111:Immunity, Cellular / Q000187:drug effects; D007249:Inflammation / Q000188:drug therapy; D018793:Interleukin-13 / Q000235:genetics*; D008024:Ligands; D051379:Mice; D008815:Mice, Inbred Strains; D010446:Peptide Fragments / Q000494:pharmacology* / Q000627:therapeutic use; D011510:Proteolipids / Q000276:immunology / Q000627:therapeutic use; D011994:Recombinant Proteins; D012183:Retrograde Degeneration / Q000517:prevention & control*
chemical_list: D018984:Epitopes, T-Lymphocyte; D018793:Interleukin-13; D008024:Ligands; D010446:Peptide Fragments; D011510:Proteolipids; D011994:Recombinant Proteins